New York, January 19, 2026, 11:19 EST — Market closed.
- AbbVie shares ended at $214.35, slipping 1.1%, following disappointing overall survival results from a late-stage epcoritamab trial.
- U.S. stock and bond markets remain closed for Martin Luther King Jr. Day. Trading will pick up again on Tuesday.
- Investors are eyeing AbbVie’s Feb. 4 earnings for updated 2026 guidance.
AbbVie Inc shares ended Friday at $214.35, slipping $2.44, or roughly 1.1%. This drop came after AbbVie and partner Genmab announced their blood cancer drug epcoritamab did not demonstrate a clear overall-survival benefit in a late-stage trial.
U.S. markets were closed Monday for Martin Luther King Jr. Day, giving investors extra time to process the latest readout ahead of the next session. That break is significant since traders often respond sharply to trial conclusions when the upcoming trigger is an earnings report rather than fresh economic data.
Epcoritamab is central to AbbVie’s efforts to expand its oncology portfolio, aiming to offset declining Humira sales. However, a miss on overall survival could stall label expansion, despite improvements in other metrics, leaving investors wary about the drug’s potential in diffuse large B-cell lymphoma.
AbbVie’s growth continues to hinge on its newer immunology drugs, Skyrizi and Rinvoq leading the charge. In the latest quarter, the company reported $4.708 billion in global Skyrizi net revenues, while Rinvoq pulled in $2.184 billion.
Genmab reported that its Phase 3 EPCORE DLBCL-1 trial enrolled 483 patients with relapsed or refractory diffuse large B-cell lymphoma, comparing subcutaneous epcoritamab to investigator’s choice chemoimmunotherapy. The study showed a progression-free survival advantage, with a hazard ratio of 0.74, although overall survival didn’t hit statistical significance (hazard ratio 0.96). CEO Jan van de Winkel called it “the first Phase 3 study evaluating a bispecific antibody monotherapy to demonstrate improvements in progression-free survival.” Genmab also flagged upcoming Phase 3 data in 2026 from trials testing epcoritamab combined with R-CHOP and lenalidomide regimens. Nasdaq
AbbVie stock now hinges on whether the survival miss puts a damper on hopes for broadening epcoritamab’s role in DLBCL beyond its current application. Additional data at a future medical meeting might change how both clinicians and investors weigh the trade-off, but no such event is scheduled yet.
The downside is clear-cut. Should regulators and doctors zero in on the absence of a statistically significant survival benefit, the drug’s growth prospects might shrink. Investors could remain cautious about how fast oncology can make up for losses in other areas.
AbbVie is set to release its full-year and Q4 2025 earnings on Wednesday, Feb. 4, ahead of the market open. The company plans to hold a webcast for the earnings call at 8 a.m. Central.
Traders will get another chance Tuesday when U.S. markets reopen. The next key date is the Feb. 4 report, with epcoritamab’s follow-through acting as the swing factor in the meantime.
